These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38256317)

  • 1. Depression: A Contributing Factor to the Clinical Course in Myasthenia Gravis Patients.
    Mihalache OA; Vilciu C; Petrescu DM; Petrescu C; Manea MC; Ciobanu AM; Ciobanu CA; Popa-Velea O; Riga S
    Medicina (Kaunas); 2023 Dec; 60(1):. PubMed ID: 38256317
    [No Abstract]   [Full Text] [Related]  

  • 2. QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis.
    Howard JF; Freimer M; O'Brien F; Wang JJ; Collins SR; Kissel JT;
    Muscle Nerve; 2017 Aug; 56(2):328-330. PubMed ID: 28010051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
    Katyal N; Narula N; Govindarajan R
    J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study.
    McPherson T; Aban I; Duda PW; Farzaneh-Far R; Wolfe GI; Kaminski HJ; Cutter G; Lee I;
    Muscle Nerve; 2020 Aug; 62(2):261-266. PubMed ID: 32369631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cigarette Smoking and Activities of Daily Living in Ocular Myasthenia Gravis.
    Gratton SM; Herro AM; Feuer WJ; Lam BL
    J Neuroophthalmol; 2016 Mar; 36(1):37-40. PubMed ID: 26457691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year follow-up of disease burden and medication changes in patients with myasthenia gravis: From the MG Patient Registry.
    Lee I; Leach JM; Aban I; McPherson T; Duda PW; Cutter G
    Muscle Nerve; 2022 Oct; 66(4):411-420. PubMed ID: 35673964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study.
    Howard JF; Vu T; Mantegazza R; Kushlaf H; Suzuki S; Wiendl H; Beasley KN; Liao S; Meisel A;
    Muscle Nerve; 2024 May; 69(5):556-565. PubMed ID: 38380691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.
    Granit V; Benatar M; Kurtoglu M; Miljković MD; Chahin N; Sahagian G; Feinberg MH; Slansky A; Vu T; Jewell CM; Singer MS; Kalayoglu MV; Howard JF; Mozaffar T;
    Lancet Neurol; 2023 Jul; 22(7):578-590. PubMed ID: 37353278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study.
    Bril V; Howard JF; Karam C; De Bleecker JL; Murai H; Utsugisawa K; Ulrichts P; Brauer E; Zhao S; Mantegazza R; Vu T;
    Eur J Neurol; 2024 Jan; 31(1):e16098. PubMed ID: 37843174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.
    Wolfe GI; Kaminski HJ; Aban IB; Minisman G; Kuo HC; Marx A; Ströbel P; Mazia C; Oger J; Cea JG; Heckmann JM; Evoli A; Nix W; Ciafaloni E; Antonini G; Witoonpanich R; King JO; Beydoun SR; Chalk CH; Barboi AC; Amato AA; Shaibani AI; Katirji B; Lecky BRF; Buckley C; Vincent A; Dias-Tosta E; Yoshikawa H; Waddington-Cruz M; Pulley MT; Rivner MH; Kostera-Pruszczyk A; Pascuzzi RM; Jackson CE; Verschuuren JJGM; Massey JM; Kissel JT; Werneck LC; Benatar M; Barohn RJ; Tandan R; Mozaffar T; Silvestri NJ; Conwit R; Sonett JR; Jaretzki A; Newsom-Davis J; Cutter GR;
    Lancet Neurol; 2019 Mar; 18(3):259-268. PubMed ID: 30692052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
    Kupersmith MJ; Latkany R; Homel P
    Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of outcome measures for myasthenia gravis subgroups.
    Luo Y; Dong X; Peng Y; Cui B; Yan C; Jin W; Li Y; Zhou R; Huang K; Yang H
    J Clin Neurosci; 2021 Sep; 91():270-275. PubMed ID: 34373039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses.
    Howard JF; Karam C; Yountz M; O'Brien FL; Mozaffar T;
    Ann Clin Transl Neurol; 2021 Jul; 8(7):1398-1407. PubMed ID: 34043280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of treatment with Fufang Huangqi decoction on dose reductions and discontinuation of pyridostigmine bromide tablets, prednisone, and tacrolimus in patients with type I or II myasthenia gravis.
    Caifeng S; Jingsheng Z; Yi L; Xueshi H; Zhanyou W; Haiou P; Wenjun Q
    J Tradit Chin Med; 2022 Oct; 42(5):810-817. PubMed ID: 36083490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study.
    Brandsema JF; Ginsberg M; Hoshino H; Mimaki M; Nagata S; Rao VK; Ruzhansky K; Suresh N; Tiongson E; Yamanouchi H; Frick G; Hicks E; Liao S; Howard JF;
    Pediatr Neurol; 2024 Jul; 156():198-207. PubMed ID: 38810600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison.
    van Steen C; Celico L; Spaepen E; Hagenacker T; Meuth SG; Ruck T; Smith AG; Bodicoat DH; de Francesco M; Iannazzo S
    Adv Ther; 2024 Jun; 41(6):2486-2499. PubMed ID: 38642198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender differences in clinical outcomes in myasthenia gravis: A prospective cohort study.
    Thomsen JLS; Vinge L; Harbo T; Andersen H
    Muscle Nerve; 2021 Nov; 64(5):538-544. PubMed ID: 34036597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leflunomide treatment in corticosteroid-dependent myasthenia gravis: an open-label pilot study.
    Chen P; Feng H; Deng J; Luo Y; Qiu L; Ou C; Liu W
    J Neurol; 2016 Jan; 263(1):83-8. PubMed ID: 26514837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studying the relationship between clinical features and mental health among late-onset myasthenia gravis patients.
    Yu L; Qiu L; Ran H; Ma Q; Lu YR; Liu WB
    World J Psychiatry; 2022 Mar; 12(3):470-482. PubMed ID: 35433329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.